Relaxin up regulates inducile nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial by Failli, Paola et al.
Relaxin up-regulates inducible nitric oxide synthase
expression and nitric oxide generation in rat
coronary endothelial cells1
PAOLA FAILLI, SILVIA NISTRI,* SILVIA QUATTRONE,* LUCA MAZZETTI,
MARIO BIGAZZI,† TATIANA BANI SACCHI,* AND DANIELE BANI*,2
Department of Preclinical and Clinical Pharmacology, *Department of Anatomy, Histology and
Forensic Medicine, Section of Histology, University of Florence, and †Prosperius Institute,
Florence, Italy
SPECIFIC AIMS
Nitric oxide (NO) -mediated vasodilatation appears to
be a primary effect of relaxin (RLX), a peptide hor-
mone of the insulin/IGF family produced mainly by the
ovaries and best known for its actions on the female
reproductive system that has recently been shown to
markedly dilatate heart blood vessels. We used rat
coronary endothelial (RCE) cells in primary culture as
a model to address the hypothesis that RLX can have a
direct action on the coronary endothelium by inducing
changes in its ability to generate NO and, if so, to clarify
the possible mechanisms of action and influence on
cell function.
PRINCIPAL FINDINGS
1. RLX increases the expression of inducible NO
synthase (NOS II) protein and mRNA in RCE cells
but has no effect on the constitutive NO synthase
(NOS III)
Examination of RCE cell cultures immunostained with
antibodies specific for NOS II and NOS III isoforms
revealed that the control cells were almost negative for
NOS II and showed a clear-cut cytoplasmic immunore-
activity for NOS III. A 24 h incubation with RLX (60
ng/ml, prepared from a highly purified porcine RLX
preparation, 2500 to 3000 U/mg, provided by O. D.
Sherwood) caused a marked increase in the immuno-
reactivity for NOS II, leaving NOS III immunoreactivity
unchanged. Western blot analysis confirmed that con-
trol RCE cells did not express NOS II but did express
detectable amounts of NOS III. A 24 h incubation with
RLX (60 ng/ml) caused the expression of NOS II and
had a negligible effect on NOS III. Addition of dexa-
methasone (8 mol/l), a well-known inhibitor of the
NOS transcription factor NF-B, together with RLX
completely abolished the RLX-induced expression of
NOS II but had no significant effect on NOS III.
Replacement of the authentic hormone with an equiv-
alent concentration of RLX inactivated with 1,2-ciclo-
hexanedione, which binds to the arginines of the
receptor binding domain of RLX and prevents the
ligand-receptor interaction, failed to increase NOS II
expression, thus confirming the specificity of the RLX
effect. Evaluation of NOS mRNA by RT-PCR (Fig. 1)
showed that, under basal conditions, RCE cells ex-
pressed both NOS II and NOS III mRNAs. A 24 h
incubation with RLX at the noted concentration caused
a clear-cut, significant elevation of the amount of NOS
II mRNA and had no effect on NOS III mRNA. As
expected, addition of dexamethasone (8 mol/l) to-
gether with RLX caused a marked, significant reduc-
tion of NOS II mRNA, which dropped to a level similar
to that of the control cultures, and a negligible reduc-
tion of NOS III mRNA.
2. RLX increases NO release and intracellular NO
generation by RCE cells
Determination of nitrite, the stable end product of NO
metabolism, in RCE cell supernatants with the Griess
reaction (expressed as nmol of nitrite/ml of culture
medium) showed that, in a 24 h incubation in medium
with no RLX added, RCE cells produced detectable
amounts of NO (8.80.1). Addition of RLX (60 ng/
ml) to the RCE cell cultures caused a significant
increase in nitrite in the medium (17.91.2; P0.001
vs. control). This effect of RLX was abrogated by the
addition of the NOS inhibitor l-NMMA (10 mol/l)
during the last 20 min of RLX incubation (9.70.4;
P0.001 vs. RLX alone), as well as by a 24 h incubation
with dexamethasone (8 mol/l) together with RLX
(3.80.1; P0.001 vs. RLX alone). In one experiment,
inactivated RLX given in the place of authentic RLX
was ineffective in increasing nitrite amount (8.9). An
RLX-induced increase in endogenous generation of
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NO ([NO]i) by RCE cells is also shown by image
analysis studies with the NO-sensitive fluorescent probe
DAF-2/DA. A 24 h incubation with RLX at the noted
concentration increased [NO]i in DAF-2/DA-loaded
RCE cell cultures challenged with the vasoconstrictor
agonist angiotensin II (AT II). This effect of RLX was
prevented by the NOS inhibitor l-NAME (10 mol/l)
added 20 min before challenging the cells with AT II.
3. RLX depresses the agonist-induced intracellular
Ca2 ([Ca2]i) transient in RCE cells
In basal conditions, [Ca2]i in RCE cells evaluated by
loading the cells with the Ca2-sensitive fluorophore
Fura 2-AM was similar in control and RLX-treated cells
(1107 vs. 1267 nmol/l, respectively). Stimulation of
control RCE cells with the vasoconstrictor agonists AT
II or thrombin caused a prompt increase in [Ca2]i,
attaining a peak 60 s after addition of the agonists and
with a decay time of 21.6  1.7 s (Fig. 2A). A 24 h
incubation of RCE cells with RLX dramatically de-
creased both peak and decay time of the agonist-
induced [Ca2]i rise (Fig. 2A). A 20 min preincubation
with either the nonspecific NOS inhibitor l-NAME
(10 mol/l) or the selective NOS II inhibitor 1400W
(1 mol/l) modified the agonist-induced [Ca2]i tran-
sient in control and RLX-treated RCE cells in different
ways (Fig. 2B). Although in the control cells, only
Figure 1. Analysis of NOS mRNA expression by RT-PCR.
A) Representative gel electrophoresis of amplification prod-
ucts for NOS II, NOS III, and the housekeeping control gene
-actin from RCE cell cultures. Lanes, A: untreated controls;
B: cultures treated with RLX (60 ng/ml for 24 h); C: cultures
treated with RLX and dexamethasone (8 mol/l for 24 h).
B) Densitometric analysis of the bands from 3 separate
experiments expressed as % changes of the values of the
controls (one-way ANOVA). Gray columns: NOS II. a) P 
0.05 vs. control; b) P  0.05 vs. RLX alone. Open column:
NOS III. RLX vs. control: not significant.
Figure 2. Evaluation of [Ca2]i. A) Representative tracings of
[Ca2]i-associated fluorescence in Fura 2-AM-loaded RCE
cells from control and RLX-treated cultures on challenge
with angiotensin II (AT II, 1 mol/l). RLX (60 ng/ml for
24 h) markedly reduces both the peak and decay time of the
[Ca2]i transient as compared with the control. AT II (1
mol/l) was added at time 0 (arrow) and maintained
throughout the experiment as indicated. B) Percent [Ca2]i
increase over the basal (left chart) and [Ca2]i transient
decay time (right chart) in 3 separate RCE cell culture
experiments. Compared with controls, RLX (60 ng/ml for
24 h) caused a significant decrease of both the parameters
assayed. Coincubation with the nonspecific NOS inhibitor
l-NMMA (10 mol/l for 20 min) or the selective NOS II
inhibitor 1400W (1 mol/l for 20 min) blunted the effect of
RLX. Significance of differences (one-way ANOVA): RLX vs.
control: P  0.001 (increase), P  0.01 (decay time); RLX vs.
RLX l-NAME: P 0.01 (both); RLX vs. RLX 1400W: P
0.05 (increase), P  0.01 (decay time); RLX  l-NAME vs.
RLX  1400W: not significant (both).
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l-NAME caused a moderate increase in the decay time
of [Ca2]i transient, in the RLX-treated cells both NOS
inhibitors were able to significantly raise both peak and
decay time. 1400W was only slightly less effective than
l-NAME in blunting the effect of RLX. These findings
suggest a predominant role of NOS II in mediating the
action of RLX on [Ca2]i in RCE cells.
CONCLUSIONS AND SIGNIFICANCE
There is general agreement that under physiological
conditions, the vasodilatatory action of NO is primarily
an endothelium-dependent process. In fact, endothe-
lial cells contain the constitutive Ca2/calmodulin-
dependent NOS III isoform that continuously produces
small amounts of NO, which cause relaxation of the
vascular wall by an autocrine/paracrine mechanism
devoted to a moment-to-moment regulation of the
vascular tone. Endothelial cells can also express induc-
ible NOS II, which synthesizes higher amounts of NO
than NOS III and can be up-regulated by different
stimuli, especially inflammatory cytokines and media-
tors. The current study provides evidence that the
vasorelaxant hormone RLX has a direct effect on
endothelial cells from rat coronary vessels. This effect
consists mainly of the up-regulation of NOS II mRNA
and protein, apparently mediated by activation of a
dexamethasone-sensitive transcription factor. This fac-
tor could be NF-B, because it has been shown to bind
to the NOS II gene promoter and to be involved in the
induction of NOS II caused by inflammatory cytokines
and lipopolysaccharides. NF-B was also found to me-
diate RLX-induced NOS II expression by arterial
smooth muscle cells in vitro.
In RCE cells, the up-regulation of NOS II ostensibly
leads to increased NO generation, which is concurrent
with a diminished responsiveness of the cells to vaso-
constrictors as judged by the clear-cut decrease in the
agonist-induced [Ca2]i transient observed in the RLX-
treated cells vs. the untreated controls. These effects of
RLX on coronary endothelial cells may account for the
overall vasodilatatory properties of this hormone in
heart blood vessels, as reported in our previous studies
where RLX was found to increase coronary flow by
acting through the NO biosynthetic pathway.
At variance with estrogens or insulin, which up-
regulate the constitutive, endothelial-type NOS III in
human and bovine endothelial cells in vitro, RLX does
not seem to influence NOS III isoform in RCE cells. In
fact, NOS III expression in terms of detectable protein
and mRNA is not significantly modified by a 24 h
incubation with RLX at the concentration tested. This
finding suggests that NOS III is not substantially in-
volved in the response of RCE cells to RLX. This view is
also indirectly supported by the results of experiments
on the depression by RLX of agonist-induced [Ca2]i
transient. In these experiments, the reduction of the
effect of RLX afforded by the selective NOS II inhibitor
1400W was nearly the same as that afforded by the
nonspecific NOS inhibitor l-NAME, suggesting that
NOS II contributes the major amount of biologically
active NO in response to RLX. Evidence shows that
NOS II may function as a ‘constitutive’ enzyme in some
cell types under physiological conditions. Once synthe-
sized on the action of different inducers, NOS II is
active for hours to days and generates large amounts of
NO, which can have beneficial effects such as anti-
atherogenic and antiapoptotic. At variance with inflam-
matory cytokines, which lead to massive NOS II induc-
tion and consequent generation of harmful NO levels,
RLX could up-regulate NOS II in RCE cells within a
physiological range. This property of RLX may there-
fore underlie a variety of cardiovascular protective
functions of endothelial-derived NO beyond vasodilata-
tion. These include the reduced expression of chemo-
kines and adhesion molecules as well as the inhibition
of smooth muscle cell proliferation in the coronary
vascular wall. RLX may afford significant protection
against cardiovascular ischemic disease, in agreement
with the results of our previous studies in rat and
guinea pig hearts subjected to ischemia and reperfu-
sion. In the above studies, RLX was also found to
significantly decrease neutrophil extravasation into the
damaged myocardium, an effect that can be ascribed to
reduced neutrophil adhesion to the coronary endothe-
lium possibly mediated by increased generation of NO
by the endothelial cells.
In conclusion, the effects of RLX on coronary endo-
thelial cells reported here could account for at least
part of the cardiovascular protective action of this
hormone we demonstrated in animal models. To our
knowledge, RLX emerges as the only hormone capable
to up-regulate NOS II in endothelial cells. Together
with estrogens, which can modulate endothelial NO
generation acting via the constitutive NOS III isoform,
RLX can be regarded as a physiological regulator of
heart microcirculation and hence of myocardial blood
perfusion. Further support for this view comes from
previous findings that the heart possesses specific re-
ceptors for RLX. On these grounds, the presence of
circulating RLX in women during fertile life may help
explain the low incidence of coronary heart disease
compared with age-matched men and postmenopausal
women.
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